ARS Wealth Advisors Group LLC Takes Position in Abbott Laboratories $ABT

ARS Wealth Advisors Group LLC bought a new stake in shares of Abbott Laboratories (NYSE:ABT) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 7,056 shares of the healthcare product maker’s stock, valued at approximately $960,000.

A number of other large investors have also recently modified their holdings of the stock. Mogy Joel R Investment Counsel Inc. boosted its stake in shares of Abbott Laboratories by 25.8% during the 2nd quarter. Mogy Joel R Investment Counsel Inc. now owns 64,441 shares of the healthcare product maker’s stock valued at $8,765,000 after purchasing an additional 13,200 shares in the last quarter. Ferguson Wellman Capital Management Inc. boosted its stake in Abbott Laboratories by 0.4% during the second quarter. Ferguson Wellman Capital Management Inc. now owns 237,617 shares of the healthcare product maker’s stock worth $32,318,000 after acquiring an additional 967 shares in the last quarter. Baker Tilly Wealth Management LLC boosted its stake in Abbott Laboratories by 48.9% during the second quarter. Baker Tilly Wealth Management LLC now owns 5,491 shares of the healthcare product maker’s stock worth $747,000 after acquiring an additional 1,803 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in Abbott Laboratories by 98.3% during the second quarter. Exchange Traded Concepts LLC now owns 207,216 shares of the healthcare product maker’s stock worth $28,183,000 after acquiring an additional 102,734 shares in the last quarter. Finally, Marshall Financial Group LLC bought a new stake in Abbott Laboratories during the second quarter worth about $1,934,000. Institutional investors own 75.18% of the company’s stock.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.46% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on ABT. Leerink Partners began coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They set a “market perform” rating and a $143.00 price objective on the stock. Royal Bank Of Canada boosted their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 15th. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Morgan Stanley upped their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Finally, Raymond James Financial dropped their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research note on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.22.

Abbott Laboratories Stock Up 0.4%

Shares of Abbott Laboratories stock opened at $134.67 on Friday. The company has a market cap of $234.39 billion, a price-to-earnings ratio of 16.88, a price-to-earnings-growth ratio of 2.54 and a beta of 0.69. The company’s 50 day moving average is $130.38 and its 200 day moving average is $131.20. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.26. The company had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.